Arvinas

Historical price data

Arvinas is a leader in the field of targeted protein degradation, developing novel therapeutics through its proprietary PROTAC® platform. The company has achieved significant clinical validation, with its lead oncology asset, vepdegestrant, demonstrating efficacy in pivotal trials for breast cancer, and its neuroscience candidate, ARV-102, showing compelling early-stage proof-of-concept in Parkinson's disease. Arvinas's strategy combines internal R&D with strategic partnerships, such as its major collaboration with Pfizer, to advance a deep pipeline and solidify its position as a platform innovator and drug developer.

Proprietary PROTAC® (PROteolysis TArgeting Chimera) platform that designs bifunctional molecules to recruit the cell's ubiquitin-proteasome system to degrade specific disease-causing proteins, enabling targeting of previously 'undruggable' targets.

Arvinas is a first-mover competing against other pure-play TPD biotechs like Kymera, Nurix, and C4 Therapeutics, as well as large pharmaceutical companies with internal TPD efforts. Its competitive advantages include first-in-human clinical validation across multiple tissues, proprietary platform learnings, and a major partnership with Pfizer.